Geçmişten Geleceğe Epilepsi Tedavisinde Antinöbet İlaçlar

Kwan P, Brodie MJ. Refractory epilepsy: mechanisms and solutions. Expert Rev Neurother. 2006;6(3):397-406.

Hauser WA, Banerjee PN. Epidemiology of epilepsy in children. In: Pellock jM, Bourgeois BFD, Dodson WE, eds. Pediatric Epilepsy. 3rd ed. New York: Demos Medical Publishing; 2008.p. 147-64.

Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004;5:553-64.

Löscher W, Klitgaard H, Twyman RE, Schmidt D. New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov 2013;12:757-76

Schmidt D. Drug treatment of epilepsy: options and limitations. Epilepsy Behav. 2009;15(1): 56-65.

Katzung Bertram G. Basic and Clinical Pharmocology The McGraw-Hill Companies, Lange Medical Publications, 2012

White, H. Steve and Smith, Misty D. and Wilcox, Karen S. Proposed mechanisms of action of currently available antiseizure drugs. Pellock’s Pediatric Epilepsy: New york: Springer Publishing Company; 2017 p. 585-602.

Vajda FJ, Eadie MJ. The clinical pharmacology of traditional antiepileptic drugs. Epileptic Disord 2014;16(4):395Y408. doi:10.1684/epd. 2014.0704.

Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Disc 2010;9:68-82.

Orhan G, Wuttke TV, Nies AT, Schwab M, Lerche H. Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data. Expert Opin Pharmacother. 2012 Aug;13(12):1807-16.

Panayiotopoulos CP. Pharmacopoeia. In: Cole H, Lemmens N, eds. A clinical guide to epileptic syndromes and their treatment, 2nd Edition, London: Springer Publication. 2009;565-627

Schachter SC. Antiseizure drugs: mechanism of action, pharmacology, and adverse effects. Garcia P, ed. Up To Date. 2018.

Gupta M, Tripp J. Phenytoin. [Updated 2020 Jul. 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021.

Cloyd JC, Gumnit RJ, McLain W. Status epilepticus. The role of intravenous phenytoin. JAMA.1980; 244: 1479–1481.

Anderson RJ. The little compound that could: How phenytoin changed drug discovery and development. Mol Interv 2009; 9(5): 208-14.

Patsalos P. N, Bourgeois B. F. D, The Epilepsy Prescriber’s Guide to Antiepileptic Drugs, Second Edition, Cambridge University Press, 2014

Contınuum MM. American Academy of Neurology 2019;25(2, epılepsy):508–536.

Vossler D. G, Weingarten M, the American Epilepsy Society Treatments Committee, Current Revıew ın Clınıcal Science, American Epilepsy Society, www.aesnet.org, 2018

Guerreiro CAM, Guerreıro MM, Mintzer S. Carbamazepine, Oxcarbazepine, and Eslicarbazepine. Treatmento of Epilepsy, Principles and Practice. Sixth ed.Wyllie E, Philadelphia; Wolters Kluwer. 2015;615-26.

Biton V, Di Memmo J, Shukla R, et al. Adjunctive lamotrigine XR for primary generalized tonic-clonic seizures in a randomized, placebo-controlled study. Epilepsy Behav. 2010;19:352

Ramaratnam S, Panebianco M, Marson AG. Lamotrigine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev, Food and Drug Administration (FDA) 2016. labelling information. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm

French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2004;62:1252.

Biton V. Rufinamide. In: Shorvon S, Perucca E, Engel JJr, eds. The treatment of epilepsy, 3rd ed. Oxford: Willey-Blackwell. 2009; 647-55.

Panayiotopoulos CP. Treatment of typical absence seizures and related epileptic syndromes. Pediatr Drugs. 2001;3:379-403

Wallace SJ. Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res. 1998;29:147-54.

Bawden HN, Camfield CS, Camfield PR, Cunningham C, Darwish H, Dooley JM, et al. The cognitive and behavioural effects of clobazam and Standard monotherapy are comparable. Canadian Study Group for Childhood Epilepsy. Epilepsy Res. 1999;33:133-43

Sattar S, Saha SK, Paveen F, Banu LA, Momen A, Ahmed AU, et al. Intermittent prophylaxis of recurrent febrile seizures with clobazam versus diazepam. Mymensingh Med J. 2014;23(4):676-85

Sills GJ, Patsalos PN, Butler E, Forrest G, Ratnaraj N, Brodie MJ. Visual field constriction: accumulation of vigabatrin but not tiagabine in the retine. Neurology. 2001;57: 196-200.

Tallian KB, Nahata MC, Lo W, Tsao CY. Pharmacokinetics of gabapentin in paediatric patients with uncontrolled seizures. J. Clin. Pharm. Ther. 2004;29(6):511–515.

Mills JK, Ruslan NE, Lewis TG, et al. Retention rate of gabapentin in children with intractable epilepsies at 1 year. Seizure. 2012;21(1):28–31.

Holmes, Gregory L. and Pearl, Phillip L. Gabapentin and pregabalin pellock’s pediatric epilepsy new york: springer publishing company;2017 p. 815—826.

Glauser TA, Cnaan A, Shinnar S. Childhood Absence Epilepsy Study Group. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010; 362:790-9.

Cho YJ, Heo K, Kim WJ, et al. Long-term efficacy and tolerability of topiramate as add-on therapy in refractory partial epilepsy: an observational study. Epilepsia. 2009;50:1910

Wirrel E, Ho AW, Hamiwka L. Sulthiame therapy for continuous spike and wave in slow-wave sleep. Pediatr Neurol. 2006;35: 204-8.

Lerman P, Nussbaum E. The use of sulthiame in myoclonic epilepsy of childhood and adolescence. Acta Neurol Scand Suppl. 1975;60: 7-12.

Lim LL, Foldvary N, Mascha E, Lee J. Acetazolamide in women with catamential epilepsy. Epilepsia. 2001;43:746-9.

Hrachovy RA, Frost JD Jr, Glaze DG. High-dose, long-duration versus low-dose short-duration corticotropin therapy for infantile spasms. J. Pediatr. 1994;124 (Pt 1):803–806.

Go CY, MacKay MT, Weiss SK, et al. Evidence-based guideline update: medical treatment of infantile spasms. Report of the guideline development subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2012;78(24):1974–1980

MacKay MT, Weiss SK, Adams-Webber T, et al. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology. 2004;62(10):1668–1681.

Huizenga MN, Fureman BE, Solteszı, Stella N. Proceedings of the Epilepsy Foundation's 2017 Cannabinoids in Epilepsy Therapy Workshop. Epilepsy Behav. 2018;85:237-42.

Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15(3):270-8.

Zuberi S, Devinsky O, Patel A, Cross JH, villaneuva v, Wirrell EC, et al. Cannabidiol (CBD) significantly decreases drop and total seizure frequency in Lennox-Gastaut syndrome (LGS): Rresults of a dose-ranging, multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE3). 32nd ınternational Epilepsy Congress; Barcelona, Spain Epilepsia. ın press. 2017.

Kwan P, Brodie MJ. Refractory epilepsy: mechanisms and solutions. Expert Rev Neurother. 2006;6(3):397-406.

Hauser WA, Banerjee PN. Epidemiology of epilepsy in children. In: Pellock jM, Bourgeois BFD, Dodson WE, eds. Pediatric Epilepsy. 3rd ed. New York: Demos Medical Publishing; 2008.p. 147-64.

Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004;5:553-64.

Löscher W, Klitgaard H, Twyman RE, Schmidt D. New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov 2013;12:757-76

Schmidt D. Drug treatment of epilepsy: options and limitations. Epilepsy Behav. 2009;15(1): 56-65.

Katzung Bertram G. Basic and Clinical Pharmocology The McGraw-Hill Companies, Lange Medical Publications, 2012

White, H. Steve and Smith, Misty D. and Wilcox, Karen S. Proposed mechanisms of action of currently available antiseizure drugs. Pellock’s Pediatric Epilepsy: New york: Springer Publishing Company; 2017 p. 585-602.

Vajda FJ, Eadie MJ. The clinical pharmacology of traditional antiepileptic drugs. Epileptic Disord 2014;16(4):395Y408. doi:10.1684/epd. 2014.0704.

Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Disc 2010;9:68-82.

Orhan G, Wuttke TV, Nies AT, Schwab M, Lerche H. Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data. Expert Opin Pharmacother. 2012 Aug;13(12):1807-16.

Panayiotopoulos CP. Pharmacopoeia. In: Cole H, Lemmens N, eds. A clinical guide to epileptic syndromes and their treatment, 2nd Edition, London: Springer Publication. 2009;565-627

Schachter SC. Antiseizure drugs: mechanism of action, pharmacology, and adverse effects. Garcia P, ed. Up To Date. 2018.

Gupta M, Tripp J. Phenytoin. [Updated 2020 Jul. 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021.

Cloyd JC, Gumnit RJ, McLain W. Status epilepticus. The role of intravenous phenytoin. JAMA.1980; 244: 1479–1481.

Anderson RJ. The little compound that could: How phenytoin changed drug discovery and development. Mol Interv 2009; 9(5): 208-14.

Patsalos P. N, Bourgeois B. F. D, The Epilepsy Prescriber’s Guide to Antiepileptic Drugs, Second Edition, Cambridge University Press, 2014

Contınuum MM. American Academy of Neurology 2019;25(2, epılepsy):508–536.

Vossler D. G, Weingarten M, the American Epilepsy Society Treatments Committee, Current Revıew ın Clınıcal Science, American Epilepsy Society, www.aesnet.org, 2018

Guerreiro CAM, Guerreıro MM, Mintzer S. Carbamazepine, Oxcarbazepine, and Eslicarbazepine. Treatmento of Epilepsy, Principles and Practice. Sixth ed.Wyllie E, Philadelphia; Wolters Kluwer. 2015;615-26.

Biton V, Di Memmo J, Shukla R, et al. Adjunctive lamotrigine XR for primary generalized tonic-clonic seizures in a randomized, placebo-controlled study. Epilepsy Behav. 2010;19:352

Ramaratnam S, Panebianco M, Marson AG. Lamotrigine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev, Food and Drug Administration (FDA) 2016. labelling information. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm

French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2004;62:1252.

Biton V. Rufinamide. In: Shorvon S, Perucca E, Engel JJr, eds. The treatment of epilepsy, 3rd ed. Oxford: Willey-Blackwell. 2009; 647-55.

Panayiotopoulos CP. Treatment of typical absence seizures and related epileptic syndromes. Pediatr Drugs. 2001;3:379-403

Wallace SJ. Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res. 1998;29:147-54.

Bawden HN, Camfield CS, Camfield PR, Cunningham C, Darwish H, Dooley JM, et al. The cognitive and behavioural effects of clobazam and Standard monotherapy are comparable. Canadian Study Group for Childhood Epilepsy. Epilepsy Res. 1999;33:133-43

Sattar S, Saha SK, Paveen F, Banu LA, Momen A, Ahmed AU, et al. Intermittent prophylaxis of recurrent febrile seizures with clobazam versus diazepam. Mymensingh Med J. 2014;23(4):676-85

Sills GJ, Patsalos PN, Butler E, Forrest G, Ratnaraj N, Brodie MJ. Visual field constriction: accumulation of vigabatrin but not tiagabine in the retine. Neurology. 2001;57: 196-200.

Tallian KB, Nahata MC, Lo W, Tsao CY. Pharmacokinetics of gabapentin in paediatric patients with uncontrolled seizures. J. Clin. Pharm. Ther. 2004;29(6):511–515.

Mills JK, Ruslan NE, Lewis TG, et al. Retention rate of gabapentin in children with intractable epilepsies at 1 year. Seizure. 2012;21(1):28–31.

Holmes, Gregory L. and Pearl, Phillip L. Gabapentin and pregabalin pellock’s pediatric epilepsy new york: springer publishing company;2017 p. 815—826.

Glauser TA, Cnaan A, Shinnar S. Childhood Absence Epilepsy Study Group. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010; 362:790-9.

Cho YJ, Heo K, Kim WJ, et al. Long-term efficacy and tolerability of topiramate as add-on therapy in refractory partial epilepsy: an observational study. Epilepsia. 2009;50:1910

Wirrel E, Ho AW, Hamiwka L. Sulthiame therapy for continuous spike and wave in slow-wave sleep. Pediatr Neurol. 2006;35: 204-8.

Lerman P, Nussbaum E. The use of sulthiame in myoclonic epilepsy of childhood and adolescence. Acta Neurol Scand Suppl. 1975;60: 7-12.

Lim LL, Foldvary N, Mascha E, Lee J. Acetazolamide in women with catamential epilepsy. Epilepsia. 2001;43:746-9.

Hrachovy RA, Frost JD Jr, Glaze DG. High-dose, long-duration versus low-dose short-duration corticotropin therapy for infantile spasms. J. Pediatr. 1994;124 (Pt 1):803–806.

Go CY, MacKay MT, Weiss SK, et al. Evidence-based guideline update: medical treatment of infantile spasms. Report of the guideline development subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2012;78(24):1974–1980

MacKay MT, Weiss SK, Adams-Webber T, et al. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology. 2004;62(10):1668–1681.

Huizenga MN, Fureman BE, Solteszı, Stella N. Proceedings of the Epilepsy Foundation's 2017 Cannabinoids in Epilepsy Therapy Workshop. Epilepsy Behav. 2018;85:237-42.

Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15(3):270-8.

Zuberi S, Devinsky O, Patel A, Cross JH, villaneuva v, Wirrell EC, et al. Cannabidiol (CBD) significantly decreases drop and total seizure frequency in Lennox-Gastaut syndrome (LGS): Rresults of a dose-ranging, multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE3). 32nd ınternational Epilepsy Congress; Barcelona, Spain Epilepsia. ın press. 2017.